In order to further interrogate whether the observed AD-related increase in YKL-40 levels is associated with other inflammatory markers, we employed an ELISA to quantify CSF GFAP levels and in addition we used an MSD multiplexed cytokine/chemokine panel to quantify pro-inflammatory markers in CSF from AD patients versus non-demented controls. This evidence concerns the gene GFAP and Alzheimer disease.